GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 71.72B |
| Revenue (ttm) | 32.17B |
| Net Income (ttm) | 5.49B |
| Shares Out | 4.01B |
| EPS (ttm) | 1.33 |
| PE Ratio | 13.45 |
| Forward PE | 10.00 |
| Dividend | 0.61 (3.40%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | 6,415,218 |
| Average Volume | 5,776,257 |
| Open | 1,786.50 |
| Previous Close | 1,795.50 |
| Day's Range | 1,777.00 - 1,798.50 |
| 52-Week Range | 1,242.50 - 1,909.73 |
| Beta | 0.25 |
| RSI | 39.93 |
| Earnings Date | Feb 4, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026
PHILADELPHIA--(BUSINESS WIRE)-- #DiseaseEducation--GSK awards $2M in COiMMUNITY Initiative grants to help close vaccination gaps, commits $3M for 2026.
Independence Bank of Kentucky Buys 52 Shares of GSK PLC (GSK)
Independence Bank of Kentucky Buys 52 Shares of GSK PLC (GSK)
GSK plc (GSK) RAPT Therapeutics, Inc. - M&A Call - Slideshow
2026-01-20. The following slide deck was published by GSK plc in conjunction with this event.
Price Over Earnings Overview: GSK
Looking into the current session, GSK Inc. (NYSE: GSK) shares are trading at $47.74, after a 0.99% drop. Over the past month, the stock decreased by 2.26% , but over the past year, it actually increa...
RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate
RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing. Click for more on RAPT and GSK.
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a def...
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
Bristol Myers Squibb and GSK stack up differently on growth, debt, pipelines and returns, making the stock-picking decision far from obvious
Pfizer exits GSK majority-owned ViiV Healthcare; Shionogi raises stake
Pfizer (PFE) stock is in focus as the company exits GSK (GSK)-owned ViiV Healthcare as Shionogi increases its stake to 21.7% in a $2.125B deal. Read more here.
TOTH FINANCIAL ADVISORY CORP Buys 19 Shares of GSK PLC (GSK)
TOTH FINANCIAL ADVISORY CORP Buys 19 Shares of GSK PLC (GSK)
Corvus Pharmaceuticals, Immunitybio, Acadia Healthcare And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones falling around 700 points on Tuesday. Shares of Corvus Pharmaceuticals Inc (NASDAQ: CRVS) rose sharply during Tuesday's session after announcing results fro...
GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics Buyout
GSK is buying Rapt Therapeutics for $2.2 billion, the companies said Tuesday. Rapt stock rocketed.
KAVAR CAPITAL PARTNERS GROUP, LLC Sells 288 Shares of GSK PLC (GSK)
KAVAR CAPITAL PARTNERS GROUP, LLC Sells 288 Shares of GSK PLC (GSK)
Wealth Management Associates, Inc. Buys 4,124 Shares of GSK PLC (GSK)
Wealth Management Associates, Inc. Buys 4,124 Shares of GSK PLC (GSK)
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) has announced the recipients of the Linked by Lupus: Optimal Care Initiative grant, awarding nearly $1 million to support national, state, and lo...
GSK and Shionogi Restructure Stake in ViiV Healthcare
GSK and Shionogi Restructure Stake in ViiV Healthcare
GSK to buy food allergy drug maker RAPT in $2.2bn deal
US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults Business live – latest updates GSK, the UK’s second-biggest drugmaker, has unveiled a $2....
RAPT Stock Surges 64% on GSK Acquisition Deal
RAPT Stock Surges 64% on GSK Acquisition Deal
GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough
GSK plc to acquire RAPT Therapeutics ... Full story available on Benzinga.com
RAPT Therapeutics To Be Acquired For $58/Shr; Stock Surges
(RTTNews) - GSK plc (GSK,GS71.DE,GSK.L), a global biopharma, announced on Tuesday that it has entered a definitive agreement to acquire RAPT Therapeutics. (RAPT) a clinical-stage biopharmaceutical com...
Biggest Market Mover: RAPT Therapeutics Stock Soars After GSK $2.2B Acquisition Deal
Biggest Market Mover: RAPT Therapeutics Stock Soars After GSK $2.2B Acquisition Deal
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.
Why Rapt Therapeutics Shares Are Trading Higher By 63%; Here Are 20 Stocks Moving Premarket
Shares of Rapt Therapeutics Inc (NASDAQ: RAPT) rose sharply in pre-market trading after GSK (NYSE: GSK) agreed to acquire the company for $58 per share for an estimated aggregate equity value of $2....
GSK to Acquire Rapt Therapeutics in $2.2 Billion Deal
GSK to Acquire Rapt Therapeutics in $2.2 Billion Deal
Is GSK’s RAPT deal a good move for the pharma giant?
GSK has agreed to acquire the US biotech RAPT Therapeutics for $2.2bn, marking the latest move by the UK drugmaker to bolster its pipeline.